Company Directory / research
PrivateFor profitresearchEmeryville, United States
Ansa Biotechnologies
Ansa Biotechnologies develops a novel DNA synthesis technology based on enzymes.
- Founded
- 2018 8 years ago
- Staff
- 51-100 band, as listed
- Followers
- - on LinkedIn
- Funding
- $83M as listed, currency not stated
Set against six million companies
Size
51-100 people: larger than 75% of companies with a size listed
Age
8 years old.
Reach
Website ranked #5,494,023 in the world for traffic, about 1k visits a month.
What it does
BiotechnologyLife ScienceTherapeutics
Funding, as listed
$83M currency not stated
- Rounds6
- LatestSeries a, Apr 2022
- Investors15, 5 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Ansa Biotechnologies, field by field. Contact details are held but never shown.
The company
- Name
- Ansa Biotechnologies
- Type
- For profit
- Status
- Private
- Founded
- 2018
- Founders
- Daniel Arlow, Jared Ellefson, Sebastian Palluk
- Industry
- research
- Categories
- Biotechnology, Life Science, Therapeutics
Where
- City
- Emeryville
- Country
- United States
- Markets
- San Francisco Bay Area, West Coast, Western US
Size and reach
- Staff band
- 51-100
- Web traffic rank
- #5,494,023
- Monthly web visits
- 1,335
Funding, as listed
- Total
- 83,419,682 (currency not stated)
- Rounds
- 6
- Latest round
- Series a
- Latest round date
- Apr 2022
- Investors
- 15
- Lead investors
- 5
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Ansa Biotechnologies may be growing as evidenced by the expansion of its Early Access Program for complex DNA synthesis, which suggests an increasing demand for its novel DNA synthesis technology. The appointment of a new CEO, as reported in multiple articles, indicates a strategic move to strengthen leadership, potentially in response to the company's growth trajectory. Furthermore, the company's preparation for the launch of its Rapid Enzymatic Synthesis product implies an advancement in its product offerings and a potential increase in market presence.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
research in United States.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.